Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
NCT04802070
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
7
Enrollment
OTHER
Sponsor class
Conditions
Sarcoma
Interventions
DRUG:
Autologous CIK
Sponsor
Prof. Franca Fagioli